CCCC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
6.6M
+7.9%
6.2M
-44.2%
11.0M
-1.9%
11.2M
+73.8%
6.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
6.6M
+7.9%
6.2M
-44.2%
11.0M
-1.9%
11.2M
+73.8%
6.5M
Operating Expenses
33.1M
-2.6%
33.9M
-0.7%
34.2M
-25.2%
45.6M
+30.5%
35.0M
R&D
24.5M
-0.5%
24.6M
-1.5%
25.0M
-3.9%
26.0M
-0.8%
26.2M
SG&A
8.6M
-7.9%
9.3M
+1.7%
9.2M
+2.9%
8.9M
+1.7%
8.8M
Operating Income
-26423000
+4.9%
-27785000
-20.0%
-23145000
+32.7%
-34412000
-20.7%
-28501000
EBITDA
-26131000
+4.6%
-27381000
-20.5%
-22717000
+2.2%
-23219000
+16.7%
-27886000
Net Income
-23635000
+5.9%
-25129000
-22.7%
-20486000
+36.3%
-32166000
-23.6%
-26020000
EPS (Basic)
$-0.18
+10.0%
$-0.20
-17.6%
$-0.17
+61.4%
$-0.44
-18.9%
$-0.37
EPS (Diluted)
$-0.18
+10.0%
$-0.20
-17.6%
$-0.17
+61.4%
$-0.44
-18.9%
$-0.37
Shares (Diluted)
130.7M
+3.7%
126.1M
+7.6%
117.2M
+61.5%
72.6M
+2.2%
71.0M
C4 Therapeutics (CCCC) โ€” Financials